Movement Alert|METIS TECHBIO-P Falls 5.19% in Regular Trading, Continued Profit-Taking After Stock Connect Inclusion Drives Over 40% Cumulative Gain Reversal

Market Focus09:38

On September 14, METIS TECHBIO-P fell 5.19% in regular trading, trading at 15.08 HKD/share, with turnover of approximately 6.53 million HKD.

On the news front, the stock has been under sustained selling pressure since September 10 as short-term profit-taking intensified. METIS TECHBIO-P was officially included in the Stock Connect program on September 7, which initially triggered a rally of over 40% within days as southbound capital flowed in. The rapid accumulation of short-term gains has led to persistent profit-taking over consecutive sessions.

The broader biotechnology sector remained weak, adding to downward pressure. Among sector peers, INNOVENT BIO fell 1.76%, QYUNS-B declined 1.48%, while AKESO edged up 0.28%. Additionally, the market is pricing in potential supply-side pressure from a cornerstone investor lock-up expiry window expected in mid-November, further weighing on sentiment.

METIS TECHBIO-P is a Beijing-based company focused on AI-driven nanomaterial innovation, with its core NanoForge platform powering solutions in drug delivery. The company reported first-half revenue of RMB 154 million, surging over 13,000% year-on-year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment